Pharmalot By Ed Silverman Drugmakers use monopoly tactics to thwart lower-cost generic competition for inhalers, analysis finds
Pharmalot By Ed Silverman High blood pressure pills are costly — but also hard to find — in some lower-income countries
Pharmalot By Ed Silverman Two dozen states side with HHS in its raucous dispute with pharma over a drug discount program
Pharmalot By Ed Silverman Greece plans to go to court to seek compensation from Novartis over a bribery scandal
Pharmalot By Ed Silverman Pharmalittle: FDA OKs new type of diabetes drug from Lilly; Early-stage biotechs are juicy targets for M&A surge
Pharmalot By Ed Silverman National Institutes of Health licenses nearly a dozen Covid-19 technologies to a WHO program
Pharmalot By Ed Silverman Arkansas becomes the latest state to sue drugmakers and PBMs over insulin pricing
Pharmalot By Ed Silverman Pharmalittle: Pfizer resists requests for study supplies of its Covid pill; WTO talks on Covid vaccine patent waivers are bogged down
Pharmalot By Ed Silverman Drugmakers win court battle over an HHS rule that would have penalized them for offering copay coupons
Pharmalot By Ed Silverman Pharmalittle: Moderna chair defends executive hiring process; analysis finds monopoly tactics preserve inhaler revenues
Pharmalot By Ed Silverman Pharmalittle: FDA declines to approve old antidepressant for Covid; U.S.-China trade fight may derail WTO Covid patent waiver
Pharmalot By Ed Silverman Pharmalittle: Aspen may close South Africa Covid vaccine plant due to lack of orders; Roche insists it can overcome latest setback
Pharmalot By Ed Silverman Pharmalittle: Seagen chief executive is arrested for domestic assault; abortion pill producer has ample supplies
Pharmalot By Ed Silverman Pharmalittle: Moderna’s new CFO leaves due to probe by former employer; Roche suffers another setback with a cancer drug
Pharmalot By Ed Silverman Why a controversial patent rights waiver could be a ‘missed opportunity’ to tackle the next pandemic
Pharmalot By Ed Silverman Pharmalittle: Pfizer to pay $11.6 billion for Biohaven; pharmacy chains face a novel trial to determine opioid liability
Pharmalot By Damian Garde Pharmalittle: Seagen CEO under investigation after alleged domestic violence; Bausch & Lomb settles for a lesser IPO
Pharmalot By Ed Silverman Pharmalittle: FDA restricts access to J&J Covid-19 vaccine; Novartis halts production of two cancer drugs over quality issues
Pharmalot By Ed Silverman Novartis suspends production of two cancer therapies over potential quality issues
Pharmalot By Ed Silverman Pharmalittle: Abortion pill demand may rise if Roe v Wade is overturned; U.S. lawmakers move toward revamping accelerated approval
Pharmalot By Ed Silverman J&J sues a behind-the-scenes company for exploiting its patient assistance program
Pharmalot By Ed Silverman Race is often overlooked in key clinical trial data used to win new drug approvals in Europe
Pharmalot By Ed Silverman FDA warns Miami University contract testing lab over falsified data, poor quality control
Pharmalot By Ed Silverman Pharmalittle: Biogen is perilously poised for the future; WTO advances controversial Covid-vaccine patent waiver
Pharmalot By Ed Silverman A compromise on patent waivers for Covid-19 vaccines takes a key step at the WTO
Pharmalot By Ed Silverman Pharmalittle: Biogen CEO exits amid Aduhelm failures; FDA eschews its own outside expert panels
Pharmalot By Ed Silverman Is the FDA taking advice from its expert panels? A new analysis points to inconsistencies in the process
Pharmalot By Ed Silverman U.N. committee urges wealthy nations to honor human rights and widen access to Covid vaccines
Pharmalot By Ed Silverman Pharmalittle: FDA declines to approve two more drugs tested in China; Pfizer Covid pill fails to prevent infection in household members